AN2 Therapeutics, Inc. (ANTX) Stock Grade

About AN2 Therapeutics, Inc.'s fundamentals

AN2 Therapeutics is a biotechnology company with a market capitalization of $180.4 million that reported no revenue growth year-over-year and generated no net profit in its latest annual period. The company posted a net loss rather than earnings, which explains the absence of meaningful profitability metrics like P/E ratio and return on equity. As a pre-revenue or early-stage biotech firm, AN2 does not pay dividends, reflecting the capital-intensive nature of drug development before commercialization.